Scientific judgment
Our scientific team examines new and established approaches. The strength of the evidence guides each recommendation, including when to act and when to hold back.
THE RADENCE CLINICAL PHILOSOPHY
To the limits of science.
But not beyond.
Guidelines are an important starting point. Then your Radence team examines whether the evidence and your circumstances support a different approach. Sometimes that means acting earlier. Sometimes it means doing less. We explain the benefits, limitations and uncertainties so you can make an informed choice.
OUR PRINCIPLES
Science is the starting point. Judgment makes it personal.
Personal relevance
Your history, biology and priorities shape which tests make sense. We explain what the findings mean for you and what you would be trading off with each option.
Follow through
Our network of carefully selected physicians helps put your plan into practice, arranging screenings, coordinating specialists and reassessing what comes next.
HOW WE THINK
The reasoning behind a Radence recommendation.
Our integrated research group of MDs and PhDs continuously evaluates the evidence that informs your personalized preventative recommendations. Four considerations guide every recommendation.
Explore Dr. Julie Chen's frameworkEvidence quality
What does the research show today and how much confidence does it support?
Benefits and risks
What is the potential upside of an intervention weighed against the likelihood and severity of harm?
Expert interpretation
How do leading specialists interpret the findings, and where do they disagree?
Personal applicability
How do your potential options fit your biology, risks, goals, and preferences?
A PERSONALIZED STANDARD OF CARE
Radence Protocols™
Our protocols translate a continuously reviewed body of science into practical recommendations. They bring together diagnostics, specialties, organ systems and disease areas—not a one-size-fits-all checklist. Your history, biology and priorities determine what applies. We explain the evidence, benefits, limits and trade-offs behind each recommendation, and update your plan as the science and your health evolve.
Read the clinical reasoning framework1Evidence reviewed by PhDs and MDs
2Recommendations tailored to you
3Clear reasoning, including uncertainty
4Revisit as evidence changes
RADENCE INSIGHTS
Earlier. Different. Sometimes, less.
What matters is why a recommendation makes sense for you.
1 / Earlier prevention
Why aim for a lower LDL, earlier?
The evidence
Standard guidelines aim for LDL under 100, and push lower only after cardiovascular disease or a heart attack. Long-term data link lower LDL, sooner, to fewer heart attacks, strokes and deaths.
The decision
Radence aims for LDL as low as possible from around age 30, with treatment options discussed with your physician. We think this is likely right, but the long-term data won't exist for 5–10 more years. We lay out the trade-offs and you decide whether to wait for data or take a reasonable chance now.
The follow-through
A target agreed with you, treatment options explained, and cardiovascular risk monitored with advanced markers and imaging so we can act before an event.
Do you want to wait for data or take a reasonable chance now?
“In business, I spent my career pricing risk before anyone else saw it. I wanted to apply that same discipline to my most important asset: my own health.”B.L. · Former CEO, PE Investor, and Longevity Advocate
2 / Earlier screening
Why start colorectal screening at 35?
The evidence
Routine colorectal screening begins at 45 for adults at average risk. Some higher-risk people already qualify earlier under existing guidelines.
The decision
Radence members start at 35. Peter's TED talk asks whether screening at 40, or even 35, can be justified. Going earlier requires a case for the added benefit, weighed against procedure risks and uncertainty. It is an individual decision, not a blanket recommendation.
The follow-through
A documented reason for your best starting age and test, a plan for any findings, and your schedule for reassessment.
An earlier test should come with a better explanation.
“I went in for my first set of tests and within a week and a half, Radence had discovered things that had direct and meaningful impact on my health that had been downplayed and overlooked.”R.G. · PE Executive, Published Author, Thought Leader, and TED speaker
3 / A personal trade-off
A BRCA result. More than one decision.
The evidence
A harmful BRCA variant can raise cancer risk. Enhanced screening and risk-reducing surgery have different benefits, limitations and consequences. The gene, age and personal circumstances matter.
The decision
One member with a BRCA mutation described feeling lost after her diagnosis. Radence helped her understand her options and risks; she remained the decision-maker.
The follow-through
Your team explains your options, engages the relevant specialists and puts your chosen plan into practice.
“Radence helped me understand which choices were best for me and also the risks. I’m still the one making the decisions at the end of the day, but I know I’m doing it with confidence and eyes wide open.”E.J. · PE Executive, College Professor
4 / Clear of hype
A promising idea. Is it ready for you?
The evidence
Exosome treatments are marketed with regenerative claims. The FDA reports no approved exosome products and has warned of serious adverse events involving unapproved products.
The decision
Radence's recommendation is to decline an unapproved exosome treatment marketed for longevity. A biological rationale does not establish a safe, effective treatment.
The follow-through
Explain what is missing, discuss established options for your goals, and revisit the question if credible human evidence changes the balance for you.
Knowing what to do and what to decline is part of protecting your health.
EARLIER DETECTION. PERSONALIZED PREVENTION.
What we measure, and why.
A test earns its place in your protocol only if its results can change what we do next. Some are simple, some require scanners, and all are chosen to generate actionable data.
The assessments shown represent the range of testing available through Radence. Your physician determines which tests are appropriate based on your medical history, individual risk factors, and clinical needs. Not every assessment is recommended for every member.
Cancer
Is there something a routine screening might miss?
What we test
WHY
To determine when your screening starts, how often it repeats, and which findings go straight to a specialist. Colorectal screening, for example, starts at 35.
Cardiovascular Health
Is plaque building while my cholesterol looks normal?
What we test
WHY
To determine whether to lower your LDL earlier than standard guidelines suggest, how far it should come down, and how closely we should monitor it. Standard panels can't tell us this.
Brain & Cognitive Health
Could my brain be changing in ways I won’t notice for years?
What we test
WHY
To create a baseline to compare against for years, and determine how closely to monitor given your genetic risk.
Metabolic Health
Is my metabolism drifting before my glucose test shows it?
What we test
WHY
To identify the focus of your nutrition and lifestyle recommendations, and whether follow-up testing is needed.
Everything Else
What does my history suggest I test for?
What we test
WHY
To identify if your prevention protocol would benefit from targeted follow-up rather than relying on the standard menu.
200+ assessments are available across five modalities. Yours include the ones that could change a decision for you. Your assessment protocol is reviewed annually and evolved as necessary.
| Modality | What it covers | Examples |
|---|---|---|
| ModalityBlood and biomarkers | What it coversMore than 150 biomarkers, drawn by our phlebotomist | ExamplesAdvanced lipid markers, glucose and insulin markers, hormones, thyroid, inflammation, nutrients, brain-health markers, cancer and plasma-cell screening, autoimmune panels |
| ModalityAdvanced imaging | What it coversWhole-body BioAtlas MRI, plus heart, vascular and focused imaging as your history indicates | ExamplesEchocardiogram, EKG, carotid ultrasound, coronary CT angiography, DEXA, low-dose lung CT, breast imaging, cardiac MRI |
| ModalityGenetics | What it coversWhole-genome sequencing, performed once and re-interpreted each year | ExamplesA panel of nearly 3,000 genes, medication genetics, polygenic risk scores, genetic counseling |
| ModalityAt-home testing | What it coversCollected in private and shipped to partner laboratories | ExamplesMulti-cancer early detection blood test, colorectal screening, hormone and nutrition panels, gut testing |
| ModalityWearables | What it coversUsed when clinically indicated | ExamplesExtended heart-rhythm monitor, at-home sleep apnea test, continuous glucose monitor |
The imaging
BioAtlas is Radence's own whole-body MRI protocol, built on higher resolution 3-Tesla scanners with advanced coils and AI denoising, and read by select radiologists trained on it. In comparison with typical whole-body MRI on lower resolution 1.5-Tesla scanners: BioAtlas scan time is 90 minutes versus 15-60 for standard MRI; BioAtlas slices are spaced 4.5 mm and are gapless versus every 5-6 mm with gaps with standard imaging; BioAtlas includes 2-3 imaging planes per region versus 1-2. The end result is superior imaging that makes it easier to compare future scans with prior ones to detect whether any finding might have been there all along or is new and potentially actionable.
The genetics
The whole genome is read, not selected regions, and interpreted against a panel of nearly 3,000 genes with credible evidence linking variants to disease. Variants are classified against current clinical evidence and explained by certified genetic counselors. Polygenic risk scores are reported only where the clinical evidence is confirmed.
The brain
Annual cognitive screening helps establish a baseline to identify meaningful changes over time. When appropriate, Radence can coordinate optional, comprehensive neuropsychological evaluations with independent specialists, at an additional cost to the member. Findings are considered alongside brain MRI, blood markers, and APOE genetics to provide a more complete picture of cognitive health.
For women
Mammography with density assessment, breast MRI for dense tissue or elevated risk (e.g., based on cancer-gene status), a full hormone and thyroid panel, and bone-density screening from age 35 rather than the standard 65.
AN EXPERT PERSPECTIVE
Data earns its value when it changes a decision.
Dr. Zahi Fayad explains how understanding changes across your records and measurements can help clinicians determine what deserves attention and what should happen next.
"The goal isn’t a million data points. The goal is discovering which thousand matter. That distinction is critical."
Zahi A. Fayad, PhD
Director, Biomedical Engineering and Imaging Institute at Mount Sinai
Radence Clinical Advisory Board member
Dr. Fayad holds stock options in Radence.